• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Jivana Biotechnology raises $1m for targeted cancer therapy

October 26, 2016 By Sarah Faulkner

Jivana BiotechnologyJivana Biotechnology raised $1 million for its preclinical work using targeted RNA-based therapies to treat a variety of cancers, according to a regulatory filing the Oak Park, Ill.-based company submitted this week.

The minimum investment from an outside investor was $50,000, the company reported, and it used an estimated $125,000 for payments to its executive officers. CEO Sidney Hopps filed the report, along with CFO Kenneth Templin.

The biotech company works on modifying a protein in cancer cells that controls cell death (apoptosis) using a process called gene silencing, in which researchers deliver RNA to specific cells to stop the cellular translation of particular genes. By stopping the production of the anti-apoptic protein, the company claims it can trigger spontaneous cancer cell death and increase cancer cell sensitivity to chemotherapy and inhibitory drugs.

The company’s website says it is filing multiple combination therapy and dosing patents, as well as filing for orphan drug designations for its therapies that it claims will target a $20 billion market.

In order to package the RNA therapeutics and deliver them to particular cells, Jivana needs a targeted delivery vehicle. The company has a targeted nanoparticle in its pipeline that it is testing in preclinical trials for breast, ovarian, lung and pancreatic cancers. Jivana is also working on 2 targeted molecular conjugates and 2 non-targeted liposomes.

“Jivana Biotechnology has exclusive global rights to a patent allowing us to deliver siRNA against a key gene target that is over-expressed in hepatocellular carcinomas (HCC),  breast, prostate, pancreatic, ovarian, thyroid, melanoma, and numerous other cancers,” the company wrote on its website. “The delivery formulations are specifically engineered to accumulate in tumors throughout the body and mediate efficient delivery of the siRNAs to the RNAi machinery in the cancer cell cytoplasm. The delivery particles are well tolerated and manufactured by Jivana Biotechnology’s partners using well-established GMP operations to ensure commercial consistency and scalability.”

Filed Under: Featured, Funding Roundup, Nanoparticles, Oncology Tagged With: Jivana Biotechnology

IN CASE YOU MISSED IT

  • Abbott could pave new roads in diabetes management with dual sensor on the horizon
  • Tandem Diabetes Care pairs t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in U.S.
  • Ypsomed, CamDiab to integrate Abbott dual glucose-ketone sensor into automated insulin delivery system
  • PharmaSens, SiBionics collab on all-in-one insulin patch pump
  • Beta Bionics to pair iLet automated insulin delivery system with Abbott’s dual glucose-ketone sensor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS